Shengnuo Bio subsidiary and actual controller prosecuted over bid-rigging in seventh national drug procurement round, with illegal gains of 10.9796 million yuan

读创财经··CN·Read original
3▲0 ▼1Impact / 5
Summary · why it matters

Shengnuo Bio announced on the evening of October 9 that its wholly owned subsidiary Chengdu Shengnuo Biopharmaceutical Co., Ltd. and actual controller and chairman Wen Yongjun recently received an indictment from the People's Procuratorate of Yuhuatai District, Nanjing, Jiangsu Province, for alleged collusive bidding in the seventh national centralized drug procurement round, with illegal gains of 10.9796 million yuan. According to the prosecution opinion from the Yuhuatai branch of the Nanjing Public Security Bureau, Shengnuo Pharmaceutical is suspected of participating in bid-rigging for octreotide acetate injection in the seventh procurement round. Relevant personnel made commitments, and Shengnuo Pharmaceutical actually won the bid in fifth place, with illegal gains of 10.9796 million yuan during the contract period. Wen Yongjun was released on bail pending trial by the Yuhuatai branch on December 18, 2024, on suspicion of bid-rigging, and was again released on bail by the Yuhuatai procuratorate on December 17, 2025. He continues to perform his duties normally during the bail period. The company has already recognized a provision for the above 10.9796 million yuan in illegal gains in its 2025 financial statements. The subsequent fine amount will be determined after the case is concluded by the People's Court of Yuhuatai District, Nanjing, Jiangsu Province, and is expected to affect the company's net profit attributable to shareholders of the listed company for this year or future years. In the first half of 2026, Shengnuo Bio achieved operating revenue of 507 million yuan, up 50.27 percent year on year, and net profit attributable to shareholders of the listed company of 135 million yuan, up 51.98 percent year on year.

Impact on assets 1

Others▼
Cheng Du Sheng Nuo Biotec Co. Ltd. A
688117
▼ NegativeRegulationrelevance

Wholly owned subsidiary and chairman indicted for bid-rigging in national drug procurement, with 10.98M yuan illegal gains and potential fines hitting net profit.

Off-coverage companies 1

成都圣诺生物制药有限公司i
Private▼ NegativeRegulationrelevance

Shengnuo Pharmaceutical is the subsidiary prosecuted for collusive bidding on octreotide acetate injection in the seventh procurement round.